Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats
- 25 October 2006
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 24 (2) , 328-335
- https://doi.org/10.1007/s11095-006-9152-9
Abstract
Purpose This study was conducted to examine the bone and body composition effects of S-4, an aryl-propionamide derived Selective Androgen Receptor Modulator (SARM) in an ovariectomy induced model of accelerated bone loss. Methods One hundred twenty female Sprague–Dawley rats aged to twenty-three weeks were randomly assigned to twelve treatment groups. Drug treatment was initiated immediately following ovariectomy and continued for one hundred twenty days. Whole body bone mineral density (BMD), body composition, and lumbar vertebrae BMD were measured by dual energy x-ray absorptiometry. More stringent regional pQCT and biomechanical strength testing was performed on excised femurs. Results We found that S-4 treatment maintained whole body and trabecular BMD, cortical content, and increased bone strength while decreasing body fat in these animals. Conclusions The data presented herein show the protective skeletal effects of S-4. Our previous reports have shown the tissue selectivity and muscle anabolic activity of S-4. Together these data suggest that S-4 could reduce the incidence of fracture via two different mechanisms (i.e., via direct effects in bone and reducing the incidence of falls through increased muscle strength). This approach to fracture reduction would be advantageous over current therapies in these patients which are primarily antiresorptive in nature.Keywords
This publication has 32 references indexed in Scilit:
- Chemistry and Structural Biology of Androgen ReceptorChemical Reviews, 2005
- Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089)Bone, 2004
- Pharmacokinetics ofS-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulatorXenobiotica, 2004
- Why Is the Age-Standardized Incidence of Low-Trauma Fractures Rising in Many Elderly Populations?Journal of Bone and Mineral Research, 2002
- Expression of estrogen receptor α and β in the epiphyseal plate of the ratBone, 2002
- Epidemiology of Osteoporotic FracturesHormone Research in Paediatrics, 2000
- The Anti‐Androgen Hydroxyflutamide and Androgens Inhibit Interleukin‐6 Production by an Androgen‐Responsive Human Osteoblastic Cell LineJournal of Bone and Mineral Research, 1999
- Emerging Issues in Androgen Replacement TherapyJournal of Clinical Endocrinology & Metabolism, 1997
- Flutamide-mediated androgen blockade evokes osteopenia in the female ratJournal of Bone and Mineral Research, 1993
- Evaluation of the role of calcitonin deficiency in ovariectomy-induced osteopeniaLife Sciences, 1984